|
KMID : 0358320080490100893
|
|
Korean Journal of Urology
2008 Volume.49 No. 10 p.893 ~ p.898
|
|
|
The Change of Prostate-specific Antigen and Prostate- specific Antigen Density in Patients with Benign Prostatic Hyperplasia after Dutasteride Treatment
|
|
Kim Byeong-Seok
Park Sung-Yul
Moon Hong-Sang
Choi Hong-Yong
Son Young-Woo
Kim Yong-Tae
Yoon Young-Eun
Lee Sang-Bong
|
|
|
Abstract
|
|
|
Purpose: Dihydrotestosterone(DHT) is key to the initiation and maintenance of abnormal prostatic growth in benign prostatic hyperplasia (BPH). Five α-reductase inhibitor reduces prostatic growth and serum prostate-specific antigen(PSA) by blocking the conversion of testosterone to DHT. Dutasteride is a dual(type 1 and 2) 5α-reductase inhibitor. We evaluated the effects of dutasteride on prostate volume, PSA, and PSA density in men with BPH.
Materials and Methods: A total of 83 men with a clinical diagnosis of BPH were treated with dutasteride and an alpha-blocker. We investigated the change in prostate volume, PSA, and PSA density 6 and 12 months after initiation of dutasteride therapy.
Results: After 6 months of dutasteride therapy, the total prostate volume was reduced from baseline by a mean of 15.46%, the PSA was reduced by a mean of 48.24%, and the PSA density was reduced by a mean of 37.97%(p＜0.001). After 12 months of dutasteride therapy, the total prostate volume was reduced from baseline by a mean of 23.3%, the PSA was reduced by a mean of 52.57%, and the PSA density was reduced by a mean of 36.2%(p＜0.001). There were no differences in the regression rate of PSA and PSA density, in contrast to prostate volume, between 6 and 12 months of dutasteride therapy by repeated measures ANOVA.
Conclusions: The findings in this study demonstrate that the actual PSA in men receiving dutasteride would be multiplied by 2 considering the PSA regression rate after 12 months.
|
|
|
KEYWORD
|
|
|
5α-reductase inhibitor, Dutasteride, Prostate-specific antigen
|
|
|
FullTexts / Linksout information
|
|
  
|
|
|
Listed journal information
|
|
  
|
|